Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$25.1M Buy
357,774
+302,934
+552% +$15.7M ﹤0.01% 2212
2026
Q1
$2.79M Sell
54,840
-1,560,559
-97% -$72.8M ﹤0.01% 5422
2025
Q4
$47.6M Sell
1,615,399
-343,295
-18% -$9.33M 0.01% 1405
2025
Q3
$50.6M Sell
1,958,694
-890,418
-31% -$24.8M 0.01% 1334
2025
Q2
$78.6M Buy
2,849,112
+1,620,401
+132% +$42.7M 0.01% 891
2025
Q1
$34.8M Sell
1,228,711
-894,997
-42% -$31.8M 0.01% 1256
2024
Q4
$88.3M Buy
2,123,708
+815,129
+62% +$39M 0.01% 792
2024
Q3
$87.5M Buy
1,308,579
+1,089,765
+498% +$100M 0.02% 714
2024
Q2
$26M Buy
218,814
+4,183
+2% +$529K ﹤0.01% 1472
2024
Q1
$22.9M Sell
214,631
-224,975
-51% -$22.7M ﹤0.01% 1648
2023
Q4
$43.7M Buy
439,606
+107,579
+32% +$9.05M 0.01% 1125
2023
Q3
$34.3M Sell
332,027
-202,372
-38% -$22.6M 0.01% 1269
2023
Q2
$64.9M Buy
534,399
+253,789
+90% +$33.9M 0.01% 834
2023
Q1
$43.1M Sell
280,610
-31,802
-10% -$5.25M 0.01% 1044
2022
Q4
$56.1M Sell
312,412
-404,328
-56% -$66.1M 0.01% 823
2022
Q3
$84.8M Buy
716,740
+343,125
+92% +$52.1M 0.02% 553
2022
Q2
$53.4M Sell
373,615
-114,180
-23% -$16.3M 0.01% 821
2022
Q1
$84M Buy
487,795
+354,840
+267% +$59.7M 0.01% 734
2021
Q4
$33.8M Sell
132,955
-568,255
-81% -$166M 0.01% 1386
2021
Q3
$270M Buy
701,210
+547,724
+357% +$202M 0.04% 406
2021
Q2
$36.1M Sell
153,486
-845,048
-85% -$151M 0.01% 1446
2021
Q1
$131M Buy
998,534
+296,592
+42% +$43M 0.02% 601
2020
Q4
$73.3M Buy
701,942
+133,878
+24% +$13.5M 0.01% 807
2020
Q3
$40.2M Sell
568,064
-41,916
-7% -$2.92M 0.01% 989
2020
Q2
$39.2M Buy
609,980
+268,354
+79% +$14.7M 0.01% 957
2020
Q1
$10.2M Buy
341,626
+216,857
+174% +$4.99M ﹤0.01% 1719
2019
Q4
$2.44M Buy
+124,769
New +$2.21M ﹤0.01% 3997
2019
Q3
Sell
-89,985
Closed -$1.33M 10598
2019
Q2
$1.32M Buy
+89,985
New +$1.93M ﹤0.01% 5070
2019
Q1
Sell
-25,494
Closed -$473K 9468
2018
Q4
$389K Buy
+25,494
New +$419K ﹤0.01% 6517

Other funds holding MRNA

Jeff Yass's MRNA Position: Q2 2026 in Review

Jeff Yass increased its Moderna (MRNA) stake by 552% in Q2 2026, buying an estimated $15.7M and bringing the position to 357,774 shares worth $25.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Jeff Yass first reported a position in MRNA in Q4 2018 and has held it in 29 quarters since. The position peaked at $270M in Q3 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Jeff Yass held 357,774 shares of Moderna worth $25.1M as of Q2 2026.
  • Jeff Yass bought 302,934 Moderna shares in Q2 2026, an estimated $15.7M.
  • Moderna made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #2212 holding.
  • Jeff Yass first reported a position in Moderna in Q4 2018 and has held it in 29 quarters since.
  • Jeff Yass's Moderna position peaked at $270M in Q3 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.